All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub
Brought to you by Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

ESMO congress 2022

Share:

Sep 12, 2022

X post image

12 Sept 2022

#ESMO22│@drclaireroddie from @uclcancer @UCLH offers further expertise on toxicities with #CART and #bispecifics, including management of ICANS and stratification of cytopenia risk and management #mmsm #lymphoma #scientificcongress

View on 

X post image

12 Sept 2022

#ESMO22│@drclaireroddie from @uclcancer @UCLH offers her expert opinion on toxicities with #CART and #bispecifics, including potential for dasatinib to manage CRS, and the strong association of HLH with CD22 #CART #mmsm #lymphoma

View on 

X post image

11 Sept 2022

#ESMO22│Evangelos Terpos from @uoaofficial further discusses the management and treatment of bone disease in young patients with #myeloma, including MOA and treatment of bone disease in patients with renal failure #MMsm #MM #medicalcongress

View on 

X post image

11 Sept 2022

#ESMO22│Evangelos Terpos from @uoaofficial discusses the management of bone disease in young patients with #myeloma, including differences between different imaging techniques, identifying lesions, and differentiation between malignant disease and osteolytic lesions #MMsm #MM

View on 

X post image

11 Sept 2022

#ESMO22│Katja Weisel from @UKEHamburg discusses the the pathology of renal impairment in young patients with #MM #myeloma

View on 

X post image

11 Sept 2022

#ESMO22│Katja Weisel from @UKEHamburg discusses the management of renal impairment in young patients with #MM #myeloma
<1 year survival if patients require dialysis
Early commencement of treatment aids renal recovery
Dose adjustment only needed for lenalidomide

View on 

X post image

11 Sept 2022

#ESMO22│ Poster 643: Jie Xu from The Shanghai Institute of Haematology presents data from a systematic review on the use of #CARTcells for the treatment of patients with #RRMM #MMsm #medicalcongress #myeloma #CART

View on 

X post image

11 Sept 2022

#ESMO22│ Poster 643: Jie Xu from The Shanghai Institute of Haematology presents data from a systematic review on the use of #CARTcells for the treatment of patients with #RRMM, detailing data from 552 patients recruited to 21 studies #MMsm #medicalcongress #myeloma #CART

View on 

X post image

11 Sept 2022

#ESMO22│further data from Poster 642 by Abigail Bailey and colleagues, on decision making at 2nd and 3rd line treatments for #myeloma #MMsm #medicalcongress #MM

View on 

X post image

11 Sept 2022

#ESMO22│Sue Pereira presents data from a real-world survey by Abigail Bailey and colleagues of 256 clinicians treating 1778 #myeloma patients, exploring decision making at 2nd and 3rd line treatments, clinical outcomes and reasons for stopping therapy #MMsm #medicalcongress #MM

View on 

X post image

10 Sept 2022

#ESMO22│Marius Mayerhoefer from @MSKCancerCenter discusses new #PET techniques in haematological malignancies, and their applications to #myeloma #medicalcongress #mmsm

View on 

X post image

10 Sept 2022

CONGRESS | #ESMO22 | @MJFzeta @MGHCancerCenter presents interim results from a phase I trial of CART-ddBCMA in #MM.
MTD: not reached, ORR: 100% across both doses (100 and 300 million #CAR T-cells). Deep & durable responses in patients with poor prognostic factors. #mmsm

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ESMO 2022Relapsed/refractory multiple myelomaNewly diagnosed multiple myelomaPlasma cell dyscrasiasEuropean Society For Medical Oncology

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox